Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)

Atea Pharmaceuticals' EBITDA Margin history spans 1 years, with the latest figure at 60.95% for Q4 2021.

  • Quarterly EBITDA Margin changed N/A to 60.95% in Q4 2021 from the year-ago period, while the trailing twelve-month figure was 36.51% through Dec 2021, changed N/A year-over-year, with the annual reading at 34.49% for FY2021, 5700.0% up from the prior year.
  • EBITDA Margin came in at 60.95% for Q4 2021, up from 85.93% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 60.95% in Q4 2021 to a low of 85.93% in Q3 2021.